Toll Free: 1-888-928-9744

Nymox Pharmaceutical Corporation - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Nymox Pharmaceutical Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Nymox Pharmaceutical Corporation - Product Pipeline Review - 2014', provides an overview of the Nymox Pharmaceutical Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nymox Pharmaceutical Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nymox Pharmaceutical Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nymox Pharmaceutical Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Nymox Pharmaceutical Corporation's pipeline products

Reasons to buy

- Evaluate Nymox Pharmaceutical Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nymox Pharmaceutical Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nymox Pharmaceutical Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nymox Pharmaceutical Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nymox Pharmaceutical Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Nymox Pharmaceutical Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Nymox Pharmaceutical Corporation Snapshot 5
Nymox Pharmaceutical Corporation Overview 5
Key Information 5
Key Facts 5
Nymox Pharmaceutical Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
Nymox Pharmaceutical Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Nymox Pharmaceutical Corporation - Pipeline Products Glance 11
Nymox Pharmaceutical Corporation - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Nymox Pharmaceutical Corporation - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Nymox Pharmaceutical Corporation - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Nymox Pharmaceutical Corporation - Drug Profiles 15
NX-1207 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Drugs for Oncology 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
NXB-4221 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NXD-1191 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NXD-3109 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NXD-5150 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NXD-9062 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NXB-5886 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
NXC-4720 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NXT-1021 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Nymox Pharmaceutical Corporation - Pipeline Analysis 26
Nymox Pharmaceutical Corporation - Pipeline Products by Route of Administration 26
Nymox Pharmaceutical Corporation - Pipeline Products by Molecule Type 27
Nymox Pharmaceutical Corporation - Recent Pipeline Updates 28
Nymox Pharmaceutical Corporation - Dormant Projects 39
Nymox Pharmaceutical Corporation - Company Statement 40
Nymox Pharmaceutical Corporation - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44
List of Tables
Nymox Pharmaceutical Corporation, Key Information 5
Nymox Pharmaceutical Corporation, Key Facts 5
Nymox Pharmaceutical Corporation - Pipeline by Indication, 2014 7
Nymox Pharmaceutical Corporation - Pipeline by Stage of Development, 2014 9
Nymox Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2014 10
Nymox Pharmaceutical Corporation - Phase III, 2014 11
Nymox Pharmaceutical Corporation - Phase II, 2014 12
Nymox Pharmaceutical Corporation - Preclinical, 2014 13
Nymox Pharmaceutical Corporation - Discovery, 2014 14
Nymox Pharmaceutical Corporation - Pipeline by Route of Administration, 2014 26
Nymox Pharmaceutical Corporation - Pipeline by Molecule Type, 2014 27
Nymox Pharmaceutical Corporation - Recent Pipeline Updates, 2014 28
Nymox Pharmaceutical Corporation - Dormant Developmental Projects,2014 39
Nymox Pharmaceutical Corporation, Subsidiaries 42 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify